872709-83-6

Upstream product

• 32263-70-0 6-benzyloxy-3,4-dihydro-2H-naphthalen-1-one 
• 3470-50-6 6-Hydroxy-1-tetralone 
• 847585-91-5 6-(benzyloxy)-1-methyl-3,4-dihydronaphthalene-2-carbaldehyde 
• 847585-90-4 7-(benzyloxy)-4-methyl-1,2-dihydronaphthalene 
• 847585-92-6 6-hydroxy-1-methyl-3,4-dihydro-naphthalene-2-carbaldehyde 
• 872709-82-5 (S)-2-methyl-3-(4-chloro-phenyl)propan-1-ol 

Relevant academic research and scientific papers

Structure-activity relationship studies of S1P agonists with a dihydronaphthalene scaffold

Structure-activity relationship (SAR) of sphingosine-1-phosphate receptor agonists with a dihydronaphthalene scaffold was investigated. Compound 1 was modified to improve S1P1 agonistic activity and in vivo peripheral lymphocyte lowering (PLL) activity without impairing selectivity over S1P 3 agonistic activity. A detailed SAR study of the terminal lipophilic part revealed that the introduction of substituents on the propylene linker and the terminal benzene ring influences in vitro and PLL activities. Compound 6n bearing a (S)-methyl group at the 2-position on the propylene linker and chlorine at the para-position on the terminal benzene ring showed potent hS1P1 agonistic activity with excellent selectivity over hS1P 3 and in vivo PLL activity in mice.

COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF

Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a substituent(s), or a heterocylcic group which contains at least one nitrogen atom and which may have a substituent(s); n represents 0 to 3, in which when n is 2 or more, a plurality of ring A's may be the same or different from one another); a salt thereof; an N-oxide form thereof; a solvate thereof; a prodrug thereof; and a medicament which includes those. The compound represented by formula (I) is capable of binding S1P receptors (in particular, EDG-1 and/or EDG-6), and useful for preventing and/or treating rejection in transplantation, autoimmune diseases, allergic diseases, etc.